Literature DB >> 26472814

Rebamipide suppresses mite-induced asthmatic responses in NC/Nga mice.

Ikuo Murakami1, Ran Zhang2, Masayuki Kubo2, Kenjiro Nagaoka2, Eri Eguchi2, Keiki Ogino3.   

Abstract

Allergic asthma caused by continuous allergen exposure evokes allergen-specific Th2 responses and is characterized by chronic airway inflammation and hyperresponsiveness. A previous report showed that rebamipide improved asthmatic symptoms in an ovalbumin/trypsin mice model. However, it is still unclear how rebamipide exerts its effects in asthma. In this study, rebamipide improved the asthmatic responses induced by mite exposure in NC/Nga mice, revealing the mechanism of this therapeutic effect. Rebamipide suppressed the infiltration of eosinophils into the airways and lung as well as attenuating the production of reactive oxygen species in tissues. In addition to these anti-inflammatory effects, rebamipide inhibited the production of IL-33, a member of the IL-1 family that drives the subsequent production of Th2-associated cytokines. These observations identify the point where rebamipide exerts its suppressive action on asthma and suggest that rebamipide has therapeutic potential in preventing mite-induced asthma.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  IL-33; asthma; eosinophil; reactive oxygen species; rebamipide

Mesh:

Substances:

Year:  2015        PMID: 26472814     DOI: 10.1152/ajplung.00194.2015

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  3 in total

1.  IL-33 Signaling in Lung Injury.

Authors:  Jing Chang; Yue-Feng Xia; Ma-Zhong Zhang; Li-Ming Zhang
Journal:  Transl Perioper Pain Med       Date:  2016

2.  Human lactoferrin induces asthmatic symptoms in NC/Nga mice.

Authors:  Kenjiro Nagaoka; Tatsuo Ito; Keiki Ogino; Eri Eguchi; Yoshihisa Fujikura
Journal:  Physiol Rep       Date:  2017-08

3.  The risk of pulmonary adverse drug reactions of rebamipide and other drugs for acid-related diseases: An analysis of the national pharmacovigilance database in South Korea.

Authors:  Bo Ram Yang; Jae-Young Lee; Myeong Gyu Kim
Journal:  J Dig Dis       Date:  2022-02-09       Impact factor: 3.366

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.